Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CRHR1 | P34998 | 7/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PARG | Q86W56 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 2/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15840324 | 0.83 | ALDH1A1 (0.37) | ALDH1A1KDM4EGLAHPGDSMN1; SMN2 | |
| SCHEMBL15840316 | 0.83 | POLB (0.35) | ALDH1A1KDM4EGLAHPGDSMN1; SMN2 | |
| SCHEMBL15840327 | 0.78 | CRHR1 (0.41) | ELANEALDH1A1KDM4ESMN1; SMN2CRHR1 | |
| SCHEMBL7014708 | 0.75 | ELANE (0.49) | ELANEALDH1A1KDM4ELMNA | |
| SCHEMBL24601717 | 0.73 | KDM4E (0.40) | ALDH1A1KDM4EGLAHPGDSMN1; SMN2 | |
| SCHEMBL15840530 | 0.72 | KDM4E (0.38) | ALDH1A1KDM4EHPGDSMN1; SMN2LMNA | |
| SCHEMBL24001986 | 0.72 | KDM4E (0.37) | ALDH1A1KDM4EGLAHPGDSMN1; SMN2 | |
| SCHEMBL25169153 | 0.72 | EGFR (0.42) | ALDH1A1KDM4EGLAHPGDSMN1; SMN2 | |
| SCHEMBL15840323 | 0.72 | GLA (0.40) | ALDH1A1KDM4EGLAHPGDSMN1; SMN2 | |
| SCHEMBL15840308 | 0.71 | PDE3B (0.43) | ALDH1A1KDM4EGLAHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160016915-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD CALISTOGA LLC. | 2016-01-21 | — | — | US | disclosed |
| US-9221795-B2 | Phosphatidylinositol 3-kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-9029384-B2 | Phosphatidylinositol 3-kinase inhibitors | Gilead Calistoga, LLC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20140371246-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD CALISTOGA LLC | 2014-12-18 | — | — | US | disclosed |
| US-20140179718-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD CALISTOGA LLC (US) | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371246-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PIK3CA, PIK3R4, PIK3R5 | ELANE 3322/4885ALDH1A1 3939/4885KDM4E 3701/4885 |
| US-20140179718-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PIK3R5, PIK3CA, PIK3R4 | ELANE 2892/4885ALDH1A1 3794/4885KDM4E 3924/4885 |
| US-20160016915-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PIK3R5, PIK3CA, PIK3R4 | ELANE 2892/4885ALDH1A1 3794/4885KDM4E 3924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.